Identification and control of unspecified impurity in trimetazidine dihydrochloride tablet formulation

12th Joint Conference on Chemistry

Jefri^1 ; Puspitasari, A.D.^2 ; Talpaneni, J.S.R.^1 ; Tjandrawinata, R.R.^1,2,3

Analytical Development, Dexa Development Center, Dexa Medica, Cikarang, Indonesia^1

Formulation Development, Dexa Development Center, Dexa Medica, Cikarang, Indonesia^2

Dexa Laboratories of Biomolecular Sciences, Dexa Medica, Cikarang, Indonesia^3

关键词: Drug substances;    European pharmacopoeias;    Residual solvents;    Retention time;    Stability study;    Tablet formulations;    Trimetazidine;    Trimetazidine dihydrochloride;   

Others  :  https://iopscience.iop.org/article/10.1088/1757-899X/349/1/012029/pdf
DOI  :  10.1088/1757-899X/349/1/012029

来源: IOP

【 摘 要 】

Trimetazidine dihydrochloride is an anti-ischemic metabolic agent which is used as drug for angina pectoris treatment. The drug substance monograph is available in European Pharmacopoeia and British Pharmacopoeia, while the drug product monograph is not available in any of the pharmacopoeias. During development of trimetazidine dihydrochloride tablet formulation, we found increase of an unspecified impurity during preliminary stability study. The unspecified impurity was identified by high performance liquid chromatography coupled with mass spectrometry (LC-MS) and the molecular weight obtained was matching with the molecular weight of N-formyl trimetazidine (m/z 295). Further experiments were performed to confirm the suspected result by injecting the impurity standard and spiking formic acid into the drug substance. The retention time of N-formyl trimetazidine was similar to the unspecified impurity in drug product. Even spiking of formic acid into drug substance showed that the suspected impurity increased with increasing concentration of formic acid. The proposed mechanism of impurity formation is via amidation of piperazine moiety of trimetazidine by formic acid which present as residual solvent in tablet binder used in the formulation. Subsequently, the impurity in our product was controlled by choosing the primary packaging which could minimize the formation of impurity.